NIOX GroupCSSPF 77 Forward PE Ratio is 17.45 as of Jun. 29, 2026. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.14 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 391 Medical Devices & Instruments companies, NIOX Group ranks better than 57.29% on this metric.
NIOX Group (OTCPK:CSSPF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
NIOX Group Forward PE Ratio Related Terms
NIOX Group Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for NIOX Group's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group Forward PE Ratio Chart
NIOX Group Annual Data
Trend
2023-12
2024-12
2025-12
Forward PE Ratio
19.12
19.23
21.40
NIOX Group Semi-Annual Data
2023-12
2024-12
2025-06
2025-12
Forward PE Ratio
19.12
19.23
25.56
21.40
CSSPF vs ABT, SYK, MDT: Forward PE Ratio Comparison
For the Medical Devices subindustry, NIOX Group's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where NIOX Group's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
NIOX Group (CSSPF) has a Forward PE Ratio of 17.45 as of Jun. 29, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on NIOX Group and its competitors. According to the industry distribution chart, NIOX Group ranks #167 out of 391 companies in the Medical Devices & Instruments industry, placing it in the top 42.7%.
Is NIOX Group's Forward PE Ratio too high?
NIOX Group's current Forward PE Ratio is 17.45. The Medical Devices & Instruments industry median Forward PE Ratio is 18.90. NIOX Group's value of 17.45 is 7.7% below this industry median. Based on the distribution chart, NIOX Group ranks #167 out of 391 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's Forward PE Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #167 out of 391 companies for Forward PE Ratio. This puts NIOX Group in the upper half of its industry. The industry median Forward PE Ratio is 18.90. NIOX Group's value of 17.45 is 7.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 18.90, based on 391 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current Forward PE Ratio of 17.45 is 7.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 18.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current Forward PE Ratio is 17.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.14, compared to a current price of $0.75 — trading 34.2% below its estimated fair value. The current Forward PE Ratio is 17.45 and 7.7% below the Medical Devices & Instruments industry median of 18.90. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For NIOX Group (CSSPF), the current Forward PE Ratio is 17.45 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.75 is trading 34.2% below its estimated GF Value™ of $1.14.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
Forward PE Ratio: 17.45
GF Value™: $1.14 vs. price of $0.75 (34.2% below fair value)
Industry Position: 7.7% below the Medical Devices & Instruments median (#167 of 391)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 